Health Populi

MARCH 19, 2019

Payors have begun to recognize the value of nudging consumers toward over-the-counter products under Medicare Advantage plans. Edelman’s health industry segments for this study are pharma, consumer health, insurance, biotech/life science, and hospitals.

BioTech 149

BioTech Life Science Leadership Medicare 149

Health Populi

OCTOBER 28, 2019

published by the National Bureau of Economic Research found a close link between electoral politics and Medicare: that is, between legislative processes in the U.S. A recent study on politics and health care spending in the U.S. Congress and healthcare spending.

Pharmaceuticals 136

Pharmaceuticals Medical Billing Medicare Mental health 136

Health Populi

MAY 14, 2018

Incentives for lowering list prices for medicines, such as FDA requiring that drug companies include list prices in ads and bringing more transparency to Medicare drug pricing and generic competition, and. ” These prescriptions for lower pharma costs contrast with what most U.S.

Pharmaceuticals 120

Pharmaceuticals Medicare Life Science BioTech 120

Healthcare IT Today

JANUARY 9, 2023

Jesse Cugliotta, Global Industry GTM Lead, Healthcare & Life Sciences at Snowflake. Patient insight management will be a key strategic pillar: Life science organizations are more confident in the business value of insights management and are increasingly willing to commit the necessary technological resources to support this need.

Health IT 90

Health IT Pharmaceuticals Drug Development Life Science 90

Health Populi

JUNE 18, 2020

The authors, Dr. Naci and Dr. Kesselheim, are affiliated with the London School of Economics and Brigham and Women’s Hospital in Boston, note that 1% of medicines dispensed under Medicare Part D and Medicaid accounted for nearly $1 in $3 of drug spending in each program in 2015. bn to $32.8 bn to $9.9 bn for Medicaid.

BioTech 191

BioTech Medicare Life Science Telehealth 191

Health Populi

MARCH 6, 2019

is prescription drug prices — that they’re too high, that the Federal government should negotiate to lower costs for Medicare enrollees, and that out-of-pocket costs for drugs should be limited. One of the only issues bringing people together in the U.S.

Pharmaceuticals 140

Pharmaceuticals Life Science Medicare BioTech 140

Health Populi

JUNE 3, 2021

adults note that expanding Medicare to including hearing aids, dental and vision coverage would be their top or an important priority, shown in the second line in the bar chart on public priorities. States to negotiate with drug companies to get lower prices on Rx meds in their state, and. On the cost-front, 90% of U.S.

Medicare 170

Medicare Life Science BioTech Pharmaceuticals 170

Health Populi

MAY 19, 2019

They don’t tend to shop around for health care or be super-engaged in their care, probably because they tend to be older and more likely to be covered by Medicare. They may be threatened by a call for “Medicare for All” given their affection for the program.

Life Science 149

Life Science BioTech Medicare Medical Billing 149